Basecamp Research secures $140M to train AI on 1M+ species data
Basecamp Research, a gene therapy firm using AI to design treatments, closed a $140 million Series C. The funding will expand its EDEN biological AI models, trained on genetic data from over a million newly sequenced species. Its approach avoids traditional manufacturing by focusing on in vivo cell therapies for a $400 billion market.
Sources: msn.com
“The round underscores how AI-driven drug discovery is shifting from small-molecule design to complex biological systems, a space where data scale and computational power are becoming competitive moats.”
What it means
While most AI drug discovery startups focus on repurposing existing data, Basecamp’s bet on sequencing new species could yield novel targets—but also faces higher technical and regulatory risk. Success hinges on whether its AI can translate biodiversity insights into therapies faster than conventional R&D. Watch for partnerships with pharma to validate its pipeline.
Read the original reporting
This is a short summary. The outlets below did the reporting.
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.